Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis - PubMed (original) (raw)
Clinical Trial
Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis
R A Hamilton et al. Br J Rheumatol. 1997 Jan.
Abstract
In order to compare the relative bioavailability of orally administered methotrexate (MTX) with i.m. administration in patients with rheumatoid arthritis, we compared the pharmacokinetics of MTX at both the usual starting dose of 7.5 mg and at higher established maintenance dosages in 21 patients. Pharmacokinetic measures were repeated approximately 6 and 18 months after baseline while patients consumed their usual maintenance doses of MTX (17.0 +/- 3.8 mg). The relative bioavailability of the usual maintenance dose of MTX was reduced by 13.5% compared with the initial dose of 7.5 mg (P = 0.026). Area under the serum concentration vs time curve (AUC) was significantly reduced with oral vs i.m. administration at usual maintenance doses (decrease of 0.729 mumol.h/l by oral administration, P = 0.027), but not at a 7.5 mg dose of MTX. Clinicians using MTX should not assume constant and complete bioavailability across the dose range used to treat patients with rheumatoid arthritis. Our observations explain the reported clinical success of switching from an oral to a parenteral route of administration in patients receiving maintenance doses of MTX.
Similar articles
- Methotrexate bioavailability after oral and subcutaneous dministration in children with juvenile idiopathic arthritis.
Tuková J, Chládek J, Nemcová D, Chládková J, Dolezalová P. Tuková J, et al. Clin Exp Rheumatol. 2009 Nov-Dec;27(6):1047-53. Clin Exp Rheumatol. 2009. PMID: 20149329 - Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis.
Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M. Hoekstra M, et al. J Rheumatol. 2004 Apr;31(4):645-8. J Rheumatol. 2004. PMID: 15088287 - Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.
Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R. Cipriani P, et al. Clin Ther. 2014 Mar 1;36(3):427-35. doi: 10.1016/j.clinthera.2014.01.014. Epub 2014 Mar 5. Clin Ther. 2014. PMID: 24612941 Review. - Inadequate response or intolerability to oral methotrexate: Is it optimal to switch to subcutaneous methotrexate prior to considering therapy with biologics?
Yadlapati S, Efthimiou P. Yadlapati S, et al. Rheumatol Int. 2016 May;36(5):627-33. doi: 10.1007/s00296-016-3447-x. Epub 2016 Mar 2. Rheumatol Int. 2016. PMID: 26936262 Review.
Cited by
- Oral methotrexate at doses 15-25 mg/week is non-inferior to parenteral regarding efficacy and safety in the treatment of rheumatoid arthritis: a systematic review and meta-analysis.
Wang F, Tang J, Li Z, Qi Y, Li G, Wang F. Wang F, et al. Clin Rheumatol. 2022 Sep;41(9):2701-2712. doi: 10.1007/s10067-022-06221-z. Epub 2022 Jun 7. Clin Rheumatol. 2022. PMID: 35672619 - Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: A meta-analysis.
Bujor AM, Janjua S, LaValley MP, Duran J, Braun J, Felson DT. Bujor AM, et al. PLoS One. 2019 Sep 6;14(9):e0221823. doi: 10.1371/journal.pone.0221823. eCollection 2019. PLoS One. 2019. PMID: 31490947 Free PMC article. - Optimising low-dose methotrexate for rheumatoid arthritis-A review.
Lucas CJ, Dimmitt SB, Martin JH. Lucas CJ, et al. Br J Clin Pharmacol. 2019 Oct;85(10):2228-2234. doi: 10.1111/bcp.14057. Epub 2019 Aug 9. Br J Clin Pharmacol. 2019. PMID: 31276602 Free PMC article. Review. - How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?-MTX in the Treat-to-Target Strategy.
Taylor PC, Balsa Criado A, Mongey AB, Avouac J, Marotte H, Mueller RB. Taylor PC, et al. J Clin Med. 2019 Apr 15;8(4):515. doi: 10.3390/jcm8040515. J Clin Med. 2019. PMID: 30991730 Free PMC article. - Methotrexate for psoriatic arthritis.
Wilsdon TD, Whittle SL, Thynne TR, Mangoni AA. Wilsdon TD, et al. Cochrane Database Syst Rev. 2019 Jan 18;1(1):CD012722. doi: 10.1002/14651858.CD012722.pub2. Cochrane Database Syst Rev. 2019. PMID: 30656673 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical